Patents by Inventor Zissis CHRONEOS

Zissis CHRONEOS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for targeting of the surfactant protein A receptor
    Patent number: 10077309
    Abstract: Provided are compositions and methods for use in prophylaxis, therapy and diagnosis of conditions which involve surfactant protein receptors (SPR) including the SPR for surfactant proteins A (SPA). Specific binding partners, including mono-clonal antibodies, for the SP-R210L and SP-R210S isoforms, and methods of using such binding partners are included. Fragments of the monoclonal antibodies, and fusion proteins that contain them are also included. Also provided are methods for prophylaxis and/or therapy for an individual in need thereof by administering to the individual an effective amount of monoclonal antibody or antigen binding fragment thereof. The monoclonal antibodies are bind with specificity to epitopes in one or both of the SP-R2100L and SP-R210S isoforms.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: September 18, 2018
    Assignee: THE PENN STATE RESEARCH FOUNDATION
    Inventors: Zissis Chroneos, Neil Christensen
  • COMPOSITIONS AND METHODS FOR TARGETING OF THE SURFACTANT PROTEIN A RECEPTOR
    Publication number: 20170158768
    Abstract: Provided are compositions and methods for use in prophylaxis, therapy and diagnosis of conditions which involve surfactant protein receptors (SPR) including the SPR for surfactant proteins A (SPA). Specific binding partners, including mono-clonal antibodies, for the SP-R210L and SP-R210S isoforms, and methods of using such binding partners are included. Fragments of the monoclonal antibodies, and fusion proteins that contain them are also included. Also provided are methods for prophylaxis and/or therapy for an individual in need thereof by administering to the individual an effective amount of monoclonal antibody or antigen binding fragment thereof. The monoclonal antibodies are bind with specificity to epitopes in one or both of the SP-R2100L and SP-R210S isoforms.
    Type: Application
    Filed: July 14, 2015
    Publication date: June 8, 2017
    Inventors: Zissis CHRONEOS, Neil CHRISTENSEN